BioVie (BIVI) KOL event summary

Introduction and agenda

• Event focused on understanding Parkinson's disease and the upcoming data readout from a clinical trial targeting both motor and non-motor symptoms.

• Updates provided on the status of Parkinson's and long COVID clinical trials, with top-line data expected by end of the current or next quarter.

• Agenda included presentations on disease mechanisms, therapeutic rationale, and Q&A.

KOL background and credentials

• Dr. Suzanne de la Monte is a Professor at Brown University, specializing in Pathology, Laboratory Medicine, Neurology, and Neurosurgery.

• She is Chief of Pathology and Laboratory Medicine at the Providence VA Medical Center.

Market insights and analysis

• Neurodegenerative diseases like Alzheimer's and Parkinson's are increasing globally, with projections of 115 million Alzheimer's cases by 2050.

• Non-motor symptoms of Parkinson's, such as depression, fatigue, and cognitive impairment, significantly impact quality of life and are often under-recognized.

• The economic burden of Parkinson's in the US is estimated at $82 billion annually, with most costs due to lost function.